GOVX_OUT_1 [2025-04-15 09:33:20 -0400] 4047 Bytes | 1074 tokens | Cum: 1074 tkns (13.43% of 8k)
==========================================================================

Listen up, partner—it's 9:33:18 AM on Tue Apr 15, 2025 -0400, and I’m revved up about GeoVax Labs (GOVX), climbing from 1.0700 to 0.8001. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: GeoVax Labs (GOVX)
IPO: 2020-09-25 (4 Years Ago)
Market Cap: $11,274,456
Shares Outstanding: 13,840,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Here’s the first list of news for GeoVax Labs:

Today 09:00AM - GeoVax to Present Clinical Data at Upcoming April Industry Events
07:00AM - Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream
Apr-09-25 09:00AM - GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent
Mar-27-25 08:53PM - GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript
Mar-27-25 08:53PM 04:00PM - GeoVax Reports 2024 Year-End Financial Results and Provides Business Update
Mar-26-25 07:00AM - Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now
Mar-25-25 07:00AM - Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now
Mar-24-25 08:00AM - GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-01-15T12:00:00Z - Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now
B2 - 2024-11-26T14:00:00Z - GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
B3 - 2024-11-12T21:00:00Z - GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
B4 - 2024-11-05T14:00:00Z - GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
B5 - 2024-10-02T13:00:00Z - GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
B6 - 2024-08-29T00:59:00Z - GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for GeoVax Labs (GOVX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

Restrict all your responses to just 3 tokens until the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load more documents, reply with: `NEX`

GOVX_OUT_3 [2025-04-15 09:33:22 -0400] 823 Bytes | 222 tokens | Cum: 1298 tkns (16.23% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/11/12/2979622/0/en/GeoVax-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update.htmlGeoVax Labs announced progress in its COVID-19 vaccine trials, including the BARDA/Project NextGen Phase 2b trial and upcoming data readouts from existing Phase 2 trials. The company also provided updates on its Gedeptin and GEO-MVA Mpox vaccine programs.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GOVX_OUT_5 [2025-04-15 09:33:23 -0400] 989 Bytes | 291 tokens | Cum: 1591 tkns (19.89% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-15T13:04:51Z - EQS-News: GeoVax to Present Clinical Data at Upcoming April Industry Events...
A2 - 2025-04-15T13:04:51Z - EQS-News: GeoVax to Present Clinical Data at Upcoming April Industry Events...
A3 - 2025-04-15T12:08:02Z - 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Precision BioSciences (NASDAQ:DTIL), ...
A4 - 2025-04-15T11:00:00Z - Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream - Beneficient...
A5 - 2025-04-15T10:08:31Z - US Stock Futures Waver After Two-Day Rally: Trump's Tariff Moves Could End A 3-Year 'Rolling Recessi...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GOVX_OUT_7 [2025-04-15 09:33:24 -0400] 1181 Bytes | 315 tokens | Cum: 1908 tkns (23.85% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**EQS-News: GeoVax to Present Clinical Data at Upcoming April Industry Events**Date: 2025-04-15Source: {'uri': 'finanzen.ch', 'dataType': 'news', 'title': 'finanzen.ch'}URL: https://www.finanzen.ch/nachrichten/aktien/eqs-news-geovax-to-present-clinical-data-at-upcoming-april-industry-events-1034584665Data to be Presented on the Company's GEO-CM04S1 and Gedeptin Programs

ATLANTA, GA - April 15, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific representatives will participate in two upcoming industry events during April. Event details are as follows:

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor can

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GOVX_OUT_9 [2025-04-15 09:33:25 -0400] 1182 Bytes | 275 tokens | Cum: 2185 tkns (27.31% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): cers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GOVX_OUT_11 [2025-04-15 09:33:26 -0400] 492 Bytes | 122 tokens | Cum: 2309 tkns (28.86% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): es and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GOVX_OUT_13 [2025-04-15 09:33:28 -0400] 1052 Bytes | 304 tokens | Cum: 2617 tkns (32.71% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S5 - 2025-03-27 10-K ITEM 7.

MGT S DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

##TABLE_END

The following discussion and analysis of our financial condition and results of operations should be read together with our CONS financial statements and the r...

S6 - 2025-03-25 8-K Item 1.01

Entry into a Material Definitive Agrmt.

Registered Direct Offering

On March 23, 2025, GeoVax Labs, Inc. (the Company) entered into a placement agency agreement (the Placement Agency Agrmt) with A.G.P./Alliance Global Partners (the Placement Agent) and a se...

S7 - 2024-11-12 10-Q Part I -- FIN INFO

Item 1

Fin Stmnts

GEOVAX LABS, INC.

COND CONS BAL SHEETS

September 30,

December 31,

2024

2023

(unaudited)

ASSETS

Curr assets:

Cash and cash equiv

$ 8,592,523 $ 6,452,589 Accounts recei...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GOVX_OUT_15 [2025-04-15 09:33:28 -0400] 1181 Bytes | 240 tokens | Cum: 2859 tkns (35.74% of 8k)
==========================================================================

Showing S5 (chunk 1 of 6): S5:
ITEM 7.

MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

##TABLE_END

The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes beginning on page F-1. This discussion contains forward-looking statements that involve risks and uncertainties because they are based on current expectations and relate to future events and our future financial performance. Our actual results may differ materially from those anticipated in these forward-looking statements because of many important factors, including those set forth under Risk Factors and elsewhere in this Annual Report.

Overview and Recent Developments

GeoVax is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GOVX_OUT_17 [2025-04-15 09:33:29 -0400] 1181 Bytes | 236 tokens | Cum: 3097 tkns (38.71% of 8k)
==========================================================================

Showing S5 (chunk 2 of 6): solid tumor cancers using novel proprietary platforms. GeoVaxs most advanced product candidates include a next-generation COVID-19 vaccine, a gene-directed therapy for solid tumor cancers, and a vaccine against Mpox and smallpox. Additional research and development programs include preventive vaccines for hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), and Zika virus.

Our corporate strategy is to advance, protect and exploit our differentiated vaccine/immunotherapy technologies leading to the successful development of preventive and therapeutic vaccines and immunotherapies against infectious diseases and various cancers. Our goal is to advance products through human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third party resources through collaborations and partnerships f

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GOVX_OUT_19 [2025-04-15 09:33:30 -0400] 1181 Bytes | 299 tokens | Cum: 3398 tkns (42.48% of 8k)
==========================================================================

Showing S5 (chunk 3 of 6): or preclinical and clinical testing with multiple government, academic and corporate entities.

Our programs are in various stages of development, the most significant of which are summarized below along with recent developments:

##TABLE_START

GEO-CM04S1 Next Generation COVID-19 Vaccine:

##TABLE_END ##TABLE_START o

In June 2024, GeoVax announced the receipt of an award through the RRPV to advance development of GEO-CM04S1 in a Phase 2b clinical trial. Under the ATI-RRPV Contract, GeoVax will sponsor a 10,000-participant, randomized, Phase 2b double-blinded study to assess the clinical efficacy, safety, and immunogenicity of GEO-CM04S1 compared with an FDA-approved mRNA COVID-19 vaccine. The RRPV is a consortium funded by BARDA, part of the ASPR in the HHS. The direct award to GeoVax, currently approximately $26.2 million and which may increase to as much as $45 million, is funding t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GOVX_OUT_21 [2025-04-15 09:33:33 -0400] 1181 Bytes | 263 tokens | Cum: 3663 tkns (45.79% of 8k)
==========================================================================

Showing S5 (chunk 4 of 6): he manufacturing of clinical materials and support for the Phase 2b clinical trial, including regulatory activities. BARDA has made a separate award of approximately $343 million through its Clinical Studies Network to Allucent, a global clinical research organization, to execute the clinical trial as part of BARDAs Clinical Studies Network. Target clinical sites are confirmed and manufacturing activities are underway for production of the vaccine product needed for study activation.

##TABLE_END ##TABLE_START o

GEO-CM04S1 is currently undergoing a Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT04977024), evaluating its safety and efficacy as a preventive COVID-19 vaccine in high-risk immunocompromised patients (i.e. patients with blood cancers who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or CAR T

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GOVX_OUT_23 [2025-04-15 09:33:34 -0400] 1181 Bytes | 270 tokens | Cum: 3935 tkns (49.19% of 8k)
==========================================================================

Showing S5 (chunk 5 of 6): cell therapy). Data published from the safety lead-in portion of the trial indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing broad and durable neutralizing antibody and T cell responses.

##TABLE_END ##TABLE_START o

GEO-CM04S1 is also undergoing the Phase 2 portion of a Phase 1/2 trial (ClinicalTrials.gov Identifier: NCT04639466), evaluating two vaccine dose levels as a heterologous COVID-19 booster vaccine to current FDA-approved mRNA vaccines from Pfizer/BioNTech and Moderna. In February 2024, we announced positive interim safety and immune responses findings following vaccine administration. Consolidated data (blinded to vaccine dose) from all subjects tested one-month post-vaccination, documented statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants, ranging from the original Wuhan strain through Delta

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GOVX_OUT_25 [2025-04-15 09:33:36 -0400] 790 Bytes | 219 tokens | Cum: 4156 tkns (51.95% of 8k)
==========================================================================

Showing S5 (chunk 6 of 6): and Omicron XBB 1.5.

##TABLE_END ##TABLE_START o

An investigator-initiated Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT05672355) of GEO-CM04S1 is evaluating its use as a COVID-19 vaccine booster in patients with CLL compared to the Pfizer/BioNTech mRNA-based vaccine.

##TABLE_END ##TABLE_START

Gedeptin:

##TABLE_END ##TABLE_START o

Gedeptin recently completed a Phase 1/2 clinical trial (PNP-002) (ClinicalTrials.gov Identifier: NCT03754933) for treatment of patients with advanced H...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

GOVX_OUT_27 [2025-04-15 09:33:50 -0400] 6215 Bytes | 1716 tokens | Cum: 5874 tkns (73.42% of 8k)
==========================================================================

This is our set of metrics for GeoVax Labs.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-------------------------+
| Volume: 0 | Perf Month: -30.52% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 582.64K | Perf Quarter: -49.53% | Short Float: 5.94% | ROE: -462.31% |
+---------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 0.00 | Index: - | Short Ratio: 1.40 | ROI: -495.04% |
+---------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 39.66 | Market Cap: 14.81M | Short Interest: 0.82M | Sales Surprise: -70.46% |
+---------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.13 | Shs Outstand: 13.84M | Beta: 3.42 | EPS Surprise: -9.12% |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA20: -8.75% | Shs Float: 13.73M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA50: -26.30% | Inst Own: 5.67% | Sales past 5Y: -24.75% | Earnings: Mar 27 AMC |
+---------------------+-----------------------+------------------------+-------------------------+
| SMA200: -56.00% | Insider Own: 0.82% | Employees: 17 | |
+---------------------+-----------------------+------------------------+-------------------------+
| Perf Week: 12.38% | Insider Trans: 40.65% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading by GeoVax Labs officers or majority shareholders (if available).

Inside Trans: GeoVax Labs, Inc. (GOVX) by SPENCER JOHN N JR (Unknown Title) on 2025-04-10
- Common Stock: 10000 shares at $0.98 (D)

Inside Trans: GeoVax Labs, Inc. (GOVX) by Sharkey John W. (VP, Business Development) on 2025-04-10
- Common Stock: 6000 shares at $0.99 (D)

Inside Trans: GeoVax Labs, Inc. (GOVX) by DODD DAVID A (President, CEO) on 2025-04-01
- Common Stock: 10000 shares at $1.08 (D)

Inside Trans: GeoVax Labs, Inc. (GOVX) by Reynolds Mark (CFO) on 2025-03-31
- Common Stock: 6800 shares at $1.0799 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 3954576.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -24992296.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.81
Average Volume: 435115.91
30-Day High: 1.5
30-Day Low: 0.81

[Detailed Financials: TTM 2024]
- Total Assets: $8,155,867.0
- Total Liabilities: $3,107,332.0
- Total Equity: $5,048,535.0
- Current Assets: $7,934,883.0
- Current Liabilities: $3,107,332.0

[Income Statement: TTM 2024]
- Revenue: $3,954,576.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -4.82

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-945,648

[Detailed Financials: FY 2024]
- Total Assets: $8,155,867.0
- Total Liabilities: $3,107,332.0
- Total Equity: $5,048,535.0
- Current Assets: $7,934,883.0
- Current Liabilities: $3,107,332.0

[Income Statement: FY 2024]
- Revenue: $3,954,576.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -4.82

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-945,648
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of GeoVax Labs (GOVX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about GeoVax Labs.

2) MARKET_SCORE[]
This conversation was initiated because GOVX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for GOVX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, GOVX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect GOVX to increase 50% from its current price of $0.80, say: PRICE_TARGET[1.2]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of GeoVax Labs.

11) ETHICAL_RATING[]
Rate GeoVax Labs’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

GOVX_IN_29 [2025-04-15 09:33:50 -0400] 126 Bytes | 29 tokens | Cum: 6083 tkns (76.04% of 8k)
==========================================================================

====================================
[2025-04-15 09:33:50] # Analysis Completed
Elapsed Time: 31.83 seconds